Compare EAF & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EAF | EMBC |
|---|---|---|
| Founded | 1886 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 199.9M |
| IPO Year | 2018 | 2021 |
| Metric | EAF | EMBC |
|---|---|---|
| Price | $6.83 | $5.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $11.75 | ★ $18.50 |
| AVG Volume (30 Days) | 275.8K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | $1.17 |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | ★ N/A | $5.31 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $2.77 |
| 52 Week High | $20.32 | $15.55 |
| Indicator | EAF | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 69.08 |
| Support Level | $6.16 | $3.01 |
| Resistance Level | $8.21 | $9.38 |
| Average True Range (ATR) | 0.43 | 0.37 |
| MACD | -0.11 | 0.09 |
| Stochastic Oscillator | 15.88 | 81.21 |
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.